Plain-English translation of NCT07630649 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called Ixoberogene soroparvovec (Ixo-vec), a gene therapy designed to help the eye produce its own protein that fights abnormal blood vessel growth. The medication is given as a single injection into the eye and is meant to provide long-lasting benefit without needing repeated eye injections like current treatments require. This study focuses on treating the second eye in people who already have wet macular degeneration in both eyes.
Wet macular degeneration currently requires repeated injections into the eye to control vision loss—sometimes many times per year. This medication aims to provide lasting protection from a single injection, reducing the burden of frequent treatments and potentially offering better long-term vision outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the medication into your second eye during an office visit. If you are new to this treatment, you may receive injections in both eyes at different times. The study team will monitor your eye health and vision at several follow-up visits to make sure the treatment is safe and working well, and to track whether you need additional anti-VEGF injections over time. The study involves about 15 participants across multiple centers.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States